Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $74.99, for a total value of $599,920.00. Following the completion of the transaction, the chief financial officer now directly owns 95,679 shares in the company, valued at approximately $7,174,968.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Guggenhime also recently made the following trade(s):

• On Thursday, April 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $61.27, for a total value of $490,160.00.
• On Monday, March 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $69.02, for a total value of $552,160.00.

Vaxcyte Stock Down 3.1 %

Shares of NASDAQ:PCVX opened at $71.36 on Thursday. Vaxcyte, Inc. has a 12-month low of $44.20 and a 12-month high of $82.04. The business has a fifty day simple moving average of $65.88 and a 200 day simple moving average of $64.03.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.28. On average, analysts forecast that Vaxcyte, Inc. will post -3.96 EPS for the current fiscal year.

Institutional Trading of Vaxcyte

Large investors have recently bought and sold shares of the business. Parallel Advisors LLC grew its holdings in Vaxcyte by 155.3% during the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after acquiring an additional 250 shares during the period. Fidelis Capital Partners LLC acquired a new stake in Vaxcyte during the 1st quarter worth about $37,000. Covestor Ltd grew its holdings in Vaxcyte by 451.7% during the 1st quarter. Covestor Ltd now owns 1,153 shares of the company’s stock worth $79,000 after acquiring an additional 944 shares during the period. Banque Cantonale Vaudoise grew its holdings in Vaxcyte by 96.7% during the 1st quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock worth $81,000 after acquiring an additional 582 shares during the period. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Vaxcyte during the 4th quarter worth about $208,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on PCVX shares. Needham & Company LLC restated a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research note on Thursday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research note on Thursday, May 9th.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.